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Although the ability of G protein-coupled receptors to
stimulate normal and aberrant cell growth has been
intensely investigated, the precise nature of the molec-
ular mechanisms underlying their transforming poten-
tial are still not fully understood. In this study, we have
taken advantage of the potent mitogenic effect of throm-
bin and the focus-forming activity of one of its receptors,
protease-activated receptor-1, to dissect how this recep-
tor coupled to Gi, Gq/11, and G12/13 transduces signals
from the membrane to the nucleus to initiate transcrip-
tional events involved in cell transformation. Using en-
dogenous and transfected thrombin receptors in NIH
3T3 cells, ectopic expression of muscarinic receptors
coupled to Gq and Gi, and chimeric G protein  sub-
units and murine fibroblasts deficient in Gq/11, and
G12/13, we show here that, although coupling to Gi is
sufficient to induce ERK activation, the ability to couple
to Gq and/or G13 is necessary to induce c-jun expres-
sion and cell transformation. Furthermore, we show
that Gq and G13 can initiate the activation of MAPK
cascades, including JNK, p38, and ERK5, which in turn
regulate the activity of transcription factors controlling
expression from the c-jun promoter. We also present
evidence that c-Jun and the kinases regulating its ex-
pression are integral components of the transforming
pathway initiated by protease-activated receptor-1.
Growth factors acting on cell-surface receptors possessing an
intrinsic tyrosine kinase activity can initiate the activation of
multiple intracellular signaling pathways, which in turn con-
trol key biological processes, including cell proliferation, differ-
entiation, adhesion, and migration and cell fate decisions (re-
viewed in Ref. 1). Subtle alterations in the normal activity of
these tyrosine kinase receptors or their intracellular down-
stream targets can have dramatic biological consequences, as
they may promote the aberrant growth and survival of tumor
cells (for review, see Ref. 2). The discovery of the mas oncogene,
the predicted structure of which resembles that of the G pro-
tein-coupled receptors (GPCRs)1 rather than a tyrosine kinase
receptor (3), provided the first evidence that heptahelical re-
ceptors can also harbor transforming potential. GPCRs repre-
sent the largest family of cell-surface receptors, and they reg-
ulate intracellular signaling pathways primarily by interacting
with heterotrimeric G proteins composed of , , and  sub-
units. Upon receptor activation, there is a conformational
change that promotes the exchange of GDP bound to the 
subunit for GTP and the release of  dimers, thereby initiat-
ing a series of signaling events that culminate in a wide variety
of cellular responses (4, 5). Constitutively activated mutant
receptors (6) and receptors persistently activated by agonists
(7, 8) were found to cause cell transformation. Furthermore,
paracrine and autocrine stimulation of GPCRs by tumor-re-
leased agonists has been implicated in different types of neo-
plasias such as small cell lung carcinoma and prostate and
gastric cancer (for review, see Refs. 9 and 10), thus highlighting
a role for the large GPCR family in carcinogenesis. However,
the molecular mechanisms underlying the transforming poten-
tial of GPCRs are still not fully understood.
Using a retroviral expression library approach to identify
novel oncogenes from a mouse myeloid progenitor cell line,
Whitehead et al. (11) identified several independent cDNAs
encoding murine PAR-1, a thrombin-stimulated GPCR. Throm-
bin is a serine protease that exerts multiple physiological ef-
fects (12). Among them, the best known function of thrombin is
its key role in blood coagulation. In addition, thrombin can act
on many cell types, eliciting a large variety of cellular re-
sponses, including the regulation of cell proliferation and inva-
sion and tumor growth (13, 14). At least three receptors for
thrombin, PAR-1, PAR-3, and PAR-4, have been cloned thus far
and found to belong to the GPCR superfamily (12). Rather than
being a direct agonist for these receptors, thrombin acts by
cleaving an Arg–Ser bond in their N-terminal extracellular
domain, thereby generating a new N terminus that functions
as a tethered agonist. The potent transforming potential of
PAR-1 suggests that its deregulated expression can promote
the aberrant activation of growth-promoting pathways. This
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receptor is known to couple effectively to the Gi, Gq, and
G13 families of G protein  subunits (reviewed in Ref. 12).
Indeed, activated forms of the Gq and G13 families can them-
selves transform NIH 3T3 cells (15, 16), supporting that at
least these G proteins and their coupled receptors can promote
cell-transforming pathways.
Of interest, thrombin can potently induce the nuclear expres-
sion of members of the AP1 transcription factor family (17),
which is composed of members of the Jun and Fos families of
nuclear proteins that bind as Jun dimers or Jun-Fos het-
erodimers to DNA sequences known as 12-O-tetradecanoyl-
phorbol-13-acetate response elements on the regulatory region
of target genes, thereby enhancing or inhibiting their expres-
sion (18, 19). In particular, thrombin can induce the rapid
expression of the c-jun proto-oncogene (17), which is a critical
molecule in the regulation of cell proliferation and neoplastic
transformation (18–20). However, the nature of the intracellu-
lar signaling route by which thrombin stimulates c-jun expres-
sion and whether its protein product, c-Jun, contributes to the
transforming ability of PAR-1 are still unknown.
In this study, we have explored the molecular mechanisms
by which endogenously expressed or overexpressed thrombin
receptors can transduce signals from the membrane into nu-
clear events participating in cell transformation. For this work,
we have used endogenous and transfected thrombin receptors,
ectopic expression of muscarinic receptors coupled to Gq and
Gi (m1 and m2, respectively), and chimeric G protein  sub-
units and murine fibroblasts deficient in Gq/11 and G12/13.
We show here that, although coupling to Gi is sufficient to
induce ERK activation, the ability to couple to Gq and/or G13
is necessary to induce c-jun expression and cell transformation.
Furthermore, we show that Gq and G13 can initiate the
activation of MAPK cascades regulating the activity of tran-
scription factors controlling the activity of the c-jun promoter.
We also present evidence that c-Jun and kinases regulating its
expression are integral components of the transforming path-
ways initiated by PAR-1.
MATERIALS AND METHODS
Cell Lines
NIH 3T3 fibroblasts were maintained in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% calf serum. Human em-
bryonic kidney 293T cells were maintained in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% fetal bovine serum. Mouse em-
bryonic fibroblasts from wild-type and Gq/11 and G12/13 knockout
animals were kept in the same media supplemented with 1 mM sodium
pyruvate and nonessential amino acids.
DNA Constructs
A plasmid encoding a luciferase gene driven by a murine wild-type
c-jun promoter, pJLuc, was kindly provided by R. Prywes (21). Plasmids
pJC6, pJC9, pJTX, pJSX, and pJSTX are pBLCAT3-based reporter
constructs carrying a chloramphenicol acetyltransferase (CAT) gene
controlled by the murine full-length c-jun promoter and its mutants, as
previously described (22). A pGL3 reporter plasmid (Promega) contain-
ing the jAP1 (TGACATCA) and MEF2 (CTATTTTTAG) sites from the
murine c-jun promoter, designated pjAP1-MEF2, was engineered by
inserting the oligonucleotide sequence 5-GTACCGTCGACTCGGGGT-
GACATCATGGGCTATTTTTAGGGAGATC-3 as an Asp718/BglII frag-
ment upstream of an SV40 minimal promoter and a luciferase gene.
Reporter plasmids with mutations in the jAP1 (pjAP1m-MEF2) or
MEF2 (pjAP1-MEF2m) site and a double mutant (pjAP1m-MEF2m)
and a plasmid carrying two jAP1 sites were prepared following the
same strategy. A similar reporter plasmid carrying an MEF2 site has
been previously reported (23). Expression vectors for HA-ERK2, HA-
JNK, HA-ERK5, HA-p38, HA-p38 (ERK6), pCEFL-MEK5DD,
pCEFL-MEK5AA, pCEV29-MEKEE, pCEFL-MEKAA, pCEFL-GST-
MKK6, pCEFL-GST-MKK6KR, pCEFL-MEKK, and constitutively ac-
tivated small G proteins Ras, RhoA, Rac1, and Cdc42 have also been
described (23–26). H-RasV12 and a dominant-negative mutant of RhoA,
RhoAN19 have been described (24). Gal4 fusion proteins, including the
transactivating domains of ATF2 (amino acids 1–96) and MEF2A (ami-
no acids 266–360) and a TATA-Gal4-driven luciferase reporter plasmid
(pGal4-Luc), and bacterially expressed GST-ATF2 and GST-MEF2C
fusion proteins were described previously (25). pcDNAIII-MKK3b-WT
and its constitutively activated (EE) and dominant-negative (AA) mu-
tants were kindly provided by J. Han (27). pCEFL-AU5-JunTAM67 has
been described (28). PAR-1, kindly provided by Dr. L. F. Brass, was
subcloned into the pCEFL vector as an EcoRI fragment. DNA encoding
a G13i5 chimera, in which five amino acids at the C terminus of Gq
were replaced with the corresponding sequence of Gi2, was prepared
by PCR amplification using pcDNA3-HA-G13 (29) as a template, and
the resulting DNA was subcloned into the pCEFL-HA vector (25) as a
BglII/EcoRI fragment. A DNA plasmid encoding a Gqi5 chimeric pro-
tein, in which five amino acids at the C terminus of Gq were replaced
with the corresponding sequence of Gi2, was a gift from Dr. B. R.
Conklin (30). Expression plasmids for constitutively activated forms of
Gq, Gi2, Gs, G12, and G13; G protein  and  subunits; and m1 and
m2 muscarinic receptors were described previously (24, 25, 29, 31).
Transfections
Transient transfections of NIH 3T3 and human embryonic kidney
293T cells cultured in 6-well plates were performed using the Lipo-
fectAMINE Plus reagent (Invitrogen) following the manufacturer’s in-
structions. Stable transfections of NIH 3T3 cells expressing the m1 or
m2 receptor (NIH-m1 and NIH-m2 cells, respectively; each expressing
100,000 receptors/cell) (8, 32) and the m2 receptor plus the G13i5 or
Gqi5 chimera (NIH-m2G13i5 and NIH-m2Gqi5 cells, respectively)
were performed using the same protocol as described above, and cells
were selected in culture medium containing Geneticin (750 g/ml).
Northern Blotting
Cells were grown to 70% confluence in 10-cm plates and serum-
starved for 20 h. They were left untreated (controls) or were treated
with 1 mM carbachol or 5 units/ml thrombin for different times. After
treatment, they were washed with cold PBS, and total RNA was ex-
tracted by homogenization in TRIzol (Invitrogen) according to the man-
ufacturer’s specifications. For Northern blotting, 10–20 g of total RNA
was fractionated on 2% formaldehyde-agarose gels, transferred to nylon
membranes, and hybridized with murine full-length 32P-labeled c-jun
cDNA probe prepared using a Prime-a-Gene labeling system (Promega).
Accuracy in gel loading and transfer was confirmed by fluorescence
under UV light upon ethidium bromide staining.
Reporter Gene Assays
Luciferase Assays—Cells were transfected with different expression
plasmids together with 0.1 g of each reporter plasmid and 0.01 g of
pRL-null (a plasmid expressing luciferase from Renilla reniformis) as
an internal control. In all cases, the total amount of plasmid DNA was
adjusted with pcDNAIII--gal (a plasmid expressing -galactosidase).
Firefly and Renilla luciferase activities present in cell lysates were
assayed using a dual-luciferase reporter system (Promega), and light
emission was quantitated using a Monolight 2010 luminometer (Ana-
lytical Luminescence Laboratory) as specified by the manufacturer.
CAT Assays—NIH 3T3 cells were transfected with different expres-
sion plasmids together with 0.1 g of each reporter plasmid and 0.5 g
of pcDNAIII--gal. After a 24-h incubation, cells were washed and lysed
using reporter lysis buffer (Promega). CAT activity was assayed in cell
extracts by incubation for 1 h in the presence of 0.25 Ci of [14C]chlor-
amphenicol (100 mCi/mmol) and 200 g/ml butyryl-CoA in 0.25 M
Tris-HCl (pH 7.4). Labeled butyrylated products were extracted using a
1:2 mixture of xylenes and 2,6,10,14-tetramethylpentadecane (Sigma),
and incorporated radioactivity was counted by liquid scintillation.
Kinase Assays
Cells were seeded at 70–80% confluence and transfected with ex-
pression vectors for HA-tagged kinases alone or in combination with
different upstream molecules. After transfection, cells were cultured for
24 h and incubated in serum-free medium overnight for ERK2 and
ERK5 and for 2 h for JNK, p38, and p38. Cells were washed with cold
PBS and lysed at 4 °C in buffer containing 25 mM HEPES (pH 7.5), 0.3
M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 20 mM
-glycerophosphate, 1 mM vanadate, 1% Triton X-100, 1 mM phenyl-
methylsulfonyl fluoride, 20 g/ml aprotinin, and 20 g/ml leupeptin.
Cleared lysates containing HA-tagged kinases were immunoprecipi-
tated at 4 °C for 2 h with anti-HA monoclonal antibody HA.11 (Berkeley
Antibody Co.). Immunocomplexes were recovered with protein
G-Sepharose (Amersham Biosciences). Beads were washed three times
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with PBS containing 1% Nonidet P-40 and 2 mM vanadate, once with
100 mM Tris (pH 7.5) and 0.5 M LiCl, and once with kinase reaction
buffer (12.5 mM MOPS (pH 7.5), 12.5 mM -glycerophosphate, 7.5 mM
MgCl2, 0.5 mM EGTA, 0.5 mM sodium fluoride, and 0.5 mM vanadate).
Samples were resuspended in 30 l of kinase reaction buffer containing
1 Ci of [-32P]ATP/reaction and 20 M unlabeled ATP. After 20 min at
30 °C, the reactions were terminated by addition of 10 l of 5 Laemmli
buffer. In vitro kinase assays were performed using 1.5 g/l myelin
basic protein (Sigma) for ERK2 and 1 g of purified, bacterially ex-
pressed GST-ATF2 for JNK, p38, and p38 and GST-MEF2C for
ERK5 as substrates, as indicated. Samples were analyzed by SDS-gel
electrophoresis on 12% (or 15% for myelin basic protein) acrylamide
gels, and autoradiography was performed with the aid of an intensify-
ing screen.
Western Blotting
HA-tagged immunoprecipitates from transiently transfected NIH
3T3 cells carrying HA-MAPK, HA-JNK, HA-ERK5, HA-p38, and HA-
p38 cDNAs were analyzed by Western blotting after SDS-PAGE using
anti-HA monoclonal antibody HA.11. Gq and G11 were detected by
rabbit anti-Gq/11 antibody (Santa Cruz Biotechnology, Inc.). G12 and
G13 were detected by a mixture of anti-G12 antibody (Santa Cruz
Biotechnology, Inc.) and anti-G13 antibody (33). Proteins were visual-
ized by enhanced chemiluminescence detection (Amersham Bio-
sciences) using horseradish peroxidase-coupled goat anti-mouse and
anti-rabbit IgGs as the secondary antibodies (Cappel).
Indirect Immunofluorescence
NIH 3T3 cells and these cells stably transfected with the m1 or m2
receptor were seeded on glass coverslips and transfected using Lipo-
fectAMINE Plus reagent as described above. 24-h serum-starved cells
were treated with 1 mM carbachol and 5 units/ml thrombin, washed
twice with 1 PBS, and then fixed and permeabilized with 4% formal-
dehyde and 0.5% Triton X-100 in 1 PBS for 10 min. After washing
with PBS, cells were blocked with 1% bovine serum albumin and incu-
bated with the indicated primary antibodies for 1 h. c-Jun was detected
using rabbit anti-c-Jun antibody (Santa Cruz Biotechnology, Inc.). Fol-
lowing incubation, cells were washed three times with 1 PBS and
incubated with the corresponding fluorescein isothiocyanate-conju-
gated secondary antibodies (1:200 dilution; Jackson ImmunoResearch
Laboratories, Inc.). Coverslips were washed three times and mounted in
Vectashield mounting medium with 4,6-diamidino-2-phenylindole (Vec-
tor Laboratories, Inc.) and viewed using a Zeiss Axiophot photomicro-
scope equipped with epifluorescence. Immunofluorescence was photo-
graphed using Eastman Kodak TMAX 3200 film.
Focus Forming Assays
NIH 3T3 cells were transfected by the calcium phosphate precipita-
tion technique with different expression plasmids together with 1 g of
pcDNAIII--gal, adjusting the total amount of plasmid DNA with
empty vector. The day after transfection, cells were washed with me-
dium supplemented with 5% calf serum and then maintained in the
same medium until foci were scored, 2–3 weeks later. Duplicate plates
were fixed with 1 PBS containing 2% (v/v) formaldehyde and 0.2%
(v/v) glutaraldehyde and stained at 37 °C for -galactosidase activity
with 1 PBS containing 2 mM MgCl2, 5 mM K3Fe(CN)6, 5 mM
K4Fe(CN)6 and 0.1% 5-bromo-4-chloro-3-indolyl--D-galactopyranoside
(X-gal) to evaluate the transfection efficiency.
RESULTS
Human PAR-1 and m1, but Not m2, Harbor Oncogenic Po-
tential—PAR-1, a GPCR activated by thrombin and other pro-
teases (34, 35) that is linked to Gi, Gq, and G12/13 subunits
(12), was cloned as an oncogene using an expression library
approach (11). Indeed, as previously reported for the murine
PAR-1 gene, human PAR-1 readily induced the appearance of
foci of transformation after 2–3 weeks of culture, as shown in
Fig. 1. Interestingly, PAR-1 was even more potent than a
Gq-coupled receptor, the m1 muscarinic receptor, which trans-
forms NIH 3T3 effectively when cells are cultured in the pres-
ence of the cholinergic agonist carbachol (8). In contrast, m2
receptors that are coupled to Gi proteins do not transform cells
in culture, thus suggesting that Gq and G13, but not Gi, can
stimulate transforming pathways in these murine fibroblasts.
c-jun Expression Is Stimulated by Transforming GPCRs, and
a Dominant Inhibitory Mutant of c-Jun Prevents Their Focus-
forming Activity—To begin addressing the molecular mecha-
nism underlying the transforming ability of these GPCRs, we
first examined whether they could stimulate the ERK signaling
route, a key component of cell growth-promoting pathways
(36), using wild-type NIH 3T3 cells, which express PAR-1 en-
dogenously, and the same cells stably transfected with the m1
or m2 receptor (NIH-m1 and NIH-m2 cells, respectively). As
shown in Fig. 2, agonist addition to NIH 3T3 cells resulted in
the potent activation of ERK. However, in repeated experi-
ments, there were no remarkable differences in the strength
and duration of the ERK signal elicited by transforming and
non-transforming GPCRs, suggesting that the ability to stim-
ulate ERK does not correlate with their transforming activity.
In the search for the molecular mechanisms underlying the
distinct biological activities of these GPCRs, we focused our
attention on nuclear responses, in particular on the expression
of the transcription factor c-Jun, the function of which has
often been associated with malignant conversion (reviewed in
Ref. 19). As shown in Fig. 2 (lower panels), activation of PAR-1
and m1 receptors induced the rapid accumulation of c-jun
mRNA. Consistently, the expression of the c-Jun protein was
also increased as revealed by the nuclear c-Jun immuno-
staining of thrombin- and carbachol-stimulated cells (Fig. 2B).
Of interest, carbachol did not induce c-jun message or c-Jun
protein expression in NIH-m2 cells, suggesting that only trans-
forming GPCRs can stimulate this particular nuclear response.
We next investigated whether the ability to trigger c-Jun
expression and transformation by PAR-1 and the m1 receptor
is two functionally related events. As shown in Fig. 3, trans-
formation induced by these receptors was potently inhibited by
the coexpression of a dominant-negative mutant form of c-Jun,
c-Jun TAM67 (37), even at concentrations that displayed a
much more limited effect on RasV12-induced transformation
(28, 38) and MEK1EE-induced transformation (Fig. 3 and data
not shown). Together, these findings indicate that the func-
tional activity of c-Jun proteins is required for abnormal cell
growth promotion in response to PAR-1.
Gq and G13, but Not Gi or  Subunits, Stimulate the
c-jun Promoter—The available results indicated that, in mu-
rine fibroblasts, receptors coupled to G12/13 and/or Gq, but
not to Gi, can transduce mitogenic signals that, in turn, pro-
mote the expression of genes involved in normal and abnormal
cell growth. This prompted us to investigate which G protein
subunits are able to induce the expression of c-jun. As an
experimental approach, we first compared the effect of throm-
bin and carbachol acting on PAR-1 and the m1 and m2 recep-
tors, respectively, on a murine c-jun promoter-driven luciferase
reporter gene (pJLuc) (22). As shown in Fig. 4A, thrombin or
PAR-1 expression alone induced the c-jun promoter by nearly
2-fold, and this was enhanced to nearly 3.5-fold when PAR-1-
transfected cells were stimulated with thrombin, whereas car-
FIG. 1. Human PAR-1 induces focus formation in NIH 3T3 cells.
NIH 3T3 cells were transfected by the calcium phosphate technique
with pcDNAIII--gal, pCEFL-PAR-1, pCEFL-m1, and pCEFL-m2 (1 g
each), as indicated. Cells were cultured in 5% calf serum, and those cells
transfected with the m1 and m2 receptors were maintained in the same
medium supplemented with 100 M carbachol (Cch). After 3 weeks, the
plates were fixed and stained. The plates shown are representative of
three to five different experiments.
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bachol activated pJLuc by 5-fold, but only in cells transfected
with the m1 receptors. In view of the correlation between c-jun
mRNA expression and reporter activation, we next studied the
effect of activated forms of G protein  subunits on the regula-
tion of pJLuc. These forms express GTPase-deficient active
subunits that can elicit effector pathways, obviating the need
for receptor stimulation (39). Thus, we cotransfected pJLuc
along with the activated forms of Gs, Gi, Gq, and G13,
which are representative members of the four G subunit fam-
ilies (40), as well as  dimers. Under these conditions, Gs,
Gi, and the  dimers failed to stimulate the c-jun promoter.
In contrast, the activated forms of Gq and G13 potently
induced pJLuc by 10- and 6-fold, respectively (Fig. 4B),
strongly suggesting that heterotrimeric G protein  subunits of
the Gq and G12/13 families can mediate the effect of activated
PAR-1 on the c-jun promoter.
Chimeric G Protein  Subunits from the Gq and G12/13
Families, Including C-terminal Gi Sequences, Promote c-jun
Expression in Response to Stimulation of Gi-coupled Recep-
tors—The prolonged exposure of cells to the constitutively ac-
tivated forms of Gq and G13 subunits could lead to secondary
effects resulting in the indirect activation of the c-jun promoter.
Thus, to confirm our previous results, we took advantage of the
availability of the Gqi5 and G13i5 chimeras, in which the
C-terminal region of the  subunits was replaced with the
corresponding region of Gi (29, 30). In this case, coexpression
of these chimeras along with the Gi-coupled m2 receptor gen-
FIG. 2. Thrombin and m1 receptors stimulate the expression of c-jun and its protein product, c-Jun, in NIH 3T3 cells. A, NIH 3T3,
NIH-m1, and NIH-m2 cells were cultured in serum-free medium for 24 h and left untreated or treated with 5 units/ml thrombin or 100 M carbachol
for the indicated time points. Upper panels, lysates were immunoprecipitated with anti-ERK2 antibody and used for kinase reactions. 32P-Labeled
myelin basic protein (MBP) used as a substrate is indicated. Data represent results from a typical experiment. Similar results were obtained in
three additional experiments. Middle and lower panels, cells were seeded in 10-cm plates and, after 24 h of serum deprivation, were left untreated
or treated with 5 units/ml thrombin or 100 M carbachol for different time points, and total RNA was extracted. Samples containing 20 g of total
RNA were fractionated and analyzed by Northern blotting using murine 32P-labeled c-jun cDNA as a probe. Total RNA present in each lane was
assessed to be equivalent by ethidium bromide staining of rRNAs. The autoradiogram corresponds to a representative experiment. B, NIH 3T3,
NIH-m1, and NIH-m2 cells were seeded on coverslips, cultured in serum-free medium for 24 h, and left untreated or treated with 5 units/ml
thrombin or 100 M carbachol for 4 h, as indicated. Cells were fixed and analyzed by immunofluorescence for c-Jun (lower panels) and nuclei labeled
with 4,6-diamidino-2-phenylindole (DAPI; upper panels).
FIG. 3. A dominant-negative c-Jun mutant inhibits the trans-
forming activity of PAR-1. NIH 3T3 cells were transfected by the
calcium phosphate technique with pcDNAIII--gal, pCEFL-m1,
pCEFL-PAR-1, or pCEFL-AU5-RasV12 (1 g) alone or in combination
with c-Jun TAM67 (0.5 g). Cells were cultured for 3 weeks in 5% calf
serum and left untreated or treated with 100 M carbachol (Cch), as
indicated, and then fixed and stained. Representative plates for each
transfection are shown.
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FIG. 4. Stimulation of PAR-1 and ac-
tivated mutants of heterotrimeric G
protein  subunits of the Gq and
G12/13 families enhances the activity
of the c-jun promoter. A, NIH 3T3 cells
were cotransfected with pJLuc and pRL-
null together with expression vectors for
-galactosidase (control), m1, m2, or
PAR-1, as indicated. 24 h after serum
starvation, cells were then exposed to ve-
hicle (control), 100 M carbachol (Cch), or
5 units/ml thrombin (Thr) for 4 h, and
lysates were assayed for dual luciferase
activity. B, cells were transfected as de-
scribed for A with expression plasmids for
-galactosidase (control), MEKK, GsQL,
GiQL, GqQL, G13QL, or G subunits.
24 h after serum starvation, cells were
lysed and assayed for dual luciferase ac-
tivity. In A and B, the data represent lu-
ciferase activity normalized to R. renifor-
mis luciferase activity present in each cell
lysate, expressed as -fold induction with
respect to control cells, and are the
means  S.E. of triplicate samples from a
typical experiment. Similar results were
obtained in three separate experiments.
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erates a system that can specifically signal downstream from
Gq and G13 and that can be turned on by agonist addition.
Because m2 receptors and Gi subunits did not activate pJLuc,
this system represents a useful approach to study the isolated
effect of Gq or G13 on the c-jun promoter. As shown in Fig.
5A, the exposure of cells expressing the m2 receptor and either
the Gqi5 or G13i5 chimera to carbachol induced c-jun,
whereas the expression of the Gqi5 or G13i5 chimera alone did
not have a major effect on pJLuc activity. To validate the
specificity of this approach, we stably transfected NIH-m2 cells
with the Gqi5 and G13i5 chimeras (NIH-m2Gqi5 and NIH-
m2G13i5 cells, respectively) and measured the expression of
c-jun mRNA upon carbachol treatment. As depicted in Fig. 5B,
the cholinergic agonist induced c-jun in both cell lines, al-
though the response was stronger in the NIH-m2G13i5 cells.
These data demonstrate that, in this setting, the Gqi5 and
G13i5 chimeras can be stimulated by m2 receptors and are
therefore capable of transmitting Gq- and G13-mediated sig-
naling pathways promoting c-jun expression, thus mimicking
the effect of activated PAR-1 and m1 receptors. Collectively,
they also indicate that each of these G protein  subunits is
sufficient to transmit signals from its coupled receptors to
the nucleus.
Activation of c-jun Expression by Thrombin Is Reduced in
Cells Derived from G12/13 and, to a Lesser Extent, Gq/11 Dou-
ble Knockout Embryos—To address which G proteins are re-
quired to signal to c-jun in response to thrombin, we used
mouse embryonic fibroblasts lacking Gq and G11 subunits or
G12 and G13 subunits (Fig. 5C), derived from Gq/11 and
G12/13 double knockout embryos, respectively (reviewed in
Refs. 41 and 42). For these experiments, we evaluated the
expression of c-jun upon thrombin addition using serum as a
control. As shown in Fig. 5D, thrombin was able to induce c-jun
expression in Gq/11 knockout cells, albeit to a more limited
FIG. 5. Activation of Gq and G13 leads to enhanced expression from the c-jun promoter. A, NIH 3T3 cells were cotransfected with
pJLuc and pR-null (0.1 and 0.01 g/plate, respectively) plus expression vectors for -galactosidase (control) or m2 along with chimeric forms of Gq
and G13 (Gqi5 and G13i5, respectively; 1 g each). 24 h after transfection and serum starvation, cells were treated for 4 h with 100 M carbachol
and collected, and lysates were assayed for dual luciferase activities. The data represent firefly luciferase activity normalized to Renilla luciferase
activity present in each sample, expressed as -fold induction relative to controls. Values are the means  S.E. of triplicate samples from a typical
experiment. Nearly identical results were obtained in four additional experiments. B, NIH 3T3 cells were stably transfected with expression vectors
for m2 along with the Gqi5 or G13i5 chimera (NIH-m2Gqi5 and NIH-m2G13i5 cells, respectively). After 24 h of starvation, cells were treated with
carbachol for the indicated periods. NIH-m1 cells treated for 20 min with carbachol were used as a positive control. After treatment, total RNA was
extracted, and 20-g samples were fractionated and analyzed by Northern blotting using murine 32P-labeled c-jun cDNA as a probe. Total RNA
present in each lane was assessed to be equivalent by ethidium bromide staining of rRNAs. The autoradiogram corresponds to a representative
experiment. C, total lysates from NIH 3T3 cells; mouse embryonic fibroblasts (MEF); Gq/11 and G12/13 knockout cells; and human embryonic
kidney 293T cells untransfected or transfected with expression vectors for Gq, G11, G12, or G13 were assayed by Western blotting (WB) to detect
the presence of Gq/11 subunits (left panels) or G12/13 subunits (right panels). D, NIH 3T3 cells, wild-type mouse embryonic fibroblasts, and Gq/11
and G12/13 knockout cells were treated with 5 units/ml thrombin for the indicated times and with 10% serum as a positive control. The expression
of c-jun mRNA was measured as described for B. The autoradiogram is representative of a typical experiment.
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extent than in murine wild-type embryonic or NIH 3T3 fibro-
blasts. In contrast, in the G12/13 knockout cells, the induction
of c-jun expression in response to thrombin was markedly
reduced. As the response to serum (which served as an internal
control) was nearly identical for all cells, these results suggest
that thrombin can signal to the c-jun promoter using Gq/11 or
G12/13, although the majority of the signal is likely provided by
the activation of G12/13. These observations also suggest that,
although both families of G protein  subunits can signal to the
nucleus independently, both of them may be required for the
full stimulation of c-jun expression by thrombin.
Distinct Response Elements on the c-jun Promoter Respond to
Gq and G13 Subunits—The c-jun promoter exhibits a num-
ber of response elements that bind transcription factors, in-
cluding SP1, CTF, AP1, and MEF2, along with two GATAA
elements (Fig. 6A) (22). Among them, the jAP1 and MEF2 sites
have been found to mediate the regulation of the c-jun pro-
moter by m1 receptors (23, 25). Thus, we asked whether these
sites contribute to Gq- and G13-induced activation of this
promoter. As shown in Fig. 6B, both subunits induced the
expression of a CAT reporter gene controlled by the murine
full-length c-jun promoter (pJC6). Mutations in the jAP1 or
MEF2 site (pJTX and pJSX plasmids, respectively) only par-
tially reduced the transcriptional response to the  subunits,
suggesting that each of these elements can independently con-
tribute to the activation of the c-jun promoter by the heterotri-
meric G proteins. However, no activation was elicited when
both sites were absent, suggesting that these sites are strictly
required for G protein-dependent activation of the c-jun pro-
moter. To further investigate whether Gq and G13 can in fact
stimulate these response elements, a fragment containing nu-
cleotides 71 to 50 from the c-jun promoter, including a
single jAP1 and MEF2 site, was inserted into the pGL3 re-
porter plasmid (pjAP1-MEF2-Luc). As shown in Fig. 6C, pjAP1-
MEF2-Luc was activated by both Gq and G13 by nearly
10-fold. Interestingly, Gq and G13 also activated reporter
plasmids carrying only a single jAP1 or MEF2 site, confirming
that both subunits can signal independently to each response
element. Taken together, these results indicate that, down-
stream from GPCRs, both Gq and G13 can activate signaling
pathways that regulate the c-jun promoter by acting specifi-
cally on the jAP1 and MEF2 sites.
Gq and G13 Subunits Can Signal to the c-jun Promoter
through MAPK Cascades—Because the activity of the tran-
scription factors bound to the jAP1 and MEF2 sites within the
c-jun promoter is controlled by distinct MAPKs, including JNK,
ERK5, p38, and p38 (25), we tested whether the inhibition of
these pathways by dominant-negative mutants blocks the ac-
tivation of pJLuc by Gq and G13. For these experiments, we
transfected NIH 3T3 cells with pJLuc along with JIP-1, which,
when overexpressed, blocks the nuclear translocation of JNK,
thereby impeding JNK-dependent gene expression regulation
(43), or with dominant-negative forms of MEK5 (MEK5AA) and
MKK3 (MEK3AA) (44). As shown in Fig. 7A, JIP-1, MEK5AA,
and MKK3AA partially inhibited the c-jun promoter-depend-
ent gene expression induced by Gq and G13. Control experi-
ments showing the specificity of these molecules in this cell
setting have been previously described (25, 28). Based on these
results, we explored whether Gq and G13 are indeed able to
activate the MAPKs involved in the regulation of the c-jun
promoter. We expressed HA epitope-tagged forms of JNK,
ERK5, p38, and p38 along with the activated forms of Gq
and G13 or control molecules in NIH 3T3 cells. As depicted in
Fig. 7B, GqQL and G13QL were able to stimulate the activity
of each of these kinases, as evidenced by an increased ability to
phosphorylate their specific substrates compared with samples
transfected with pcDNAIII--Gal as a negative control. the
positive controls used were activation of JNK by MEKK, ERK5
by MEK5DD, and p38 and p38 by MEK3EE. In contrast, the
activated forms of these G protein  subunits failed to stimu-
late ERK2 under identical experimental conditions (data not
shown), as previously reported in other cell types (45). These
results indicate that expression of the activated forms of Gq
and G13 can elevate the enzymatic activity of MAPKs involved
in the stimulation of the c-jun promoter.
The Transactivating Activity of Transcription Factors Bound
to the jAP1 and MEF2 Response Elements Can Be Stimulated
by Gq and G13 Subunits—As previously described (9, 46, 47),
supershift analysis showed that the c-Jun and ATF2 proteins
are the most prominent nuclear proteins binding the jAP1 site
in NIH 3T3 cells and other cell types. With regard to the MEF2
site, our previous results indicate that MEF2A and MEF2D are
expressed in NIH 3T3 cells and that the activity of MEF2A is
regulated by ERK5, p38, and p38 (25). To assay whether
activated mutants of Gq and G13 are able to stimulate the
transactivation domain of the Jun, ATF2, and MEF2A pro-
teins, we fused these domains to the yeast transcription factor
Gal4 (9) and assessed their ability to stimulate expression from
a Gal4-regulated reporter plasmid, pGal4-Luc. Both GqQL
and G13QL significantly enhanced the transcriptional activity
of Gal4-c-Jun, Gal4-MEF2A, and Gal4-ATF2, as shown in Fig.
8. Cotransfection with MEK5DD  ERK5, which specifically
activates MEF2A, and with MEKK, which stimulates ATF2
and c-Jun (44), served as a positive control. Collectively, these
findings suggest that Gq and G13 and their coupled recep-
tors, including PAR-1, promote c-jun expression through mul-
tiple MAPK cascades that converge to stimulate the activity of
transcription factors regulating the activity of the c-jun
promoter.
The JNK, p38, and ERK5 Pathways Are Integral Compo-
nents of the Transforming Pathway Elicited by PAR-1—Based
on the role of JNK, p38 isoforms, and ERK5 in the activation of
the c-jun promoter by Gq and G13 and their coupled recep-
tors, we next asked whether these kinases participate in the
transforming ability of PAR-1 in NIH 3T3 cells. Thus, we
assayed the focus-forming activity of PAR-1 in the presence of
molecules interfering with the activation of each of these
MAPK pathways, such as JIP-1, MKK3AA, and MEK5AA. As
depicted in Fig. 9, these molecules, which limit the activation of
the JNK, p38, and ERK5 pathways, respectively, were able to
reduce the transforming activity of PAR-1. In contrast, none of
these dominant-negative forms affected the focus-forming ac-
tivity of an activated form of MEK, MEKEE, which was used as
a specificity control. Parallel plates transfected with the same
DNAs and -galactosidase were fixed and stained for -galac-
tosidase and showed no difference in transfection efficiency
(data not shown). Taken together, these results indicate that
the activation of JNK, p38 isoforms, and ERK5 contributes to
the transforming potential of PAR-1.
DISCUSSION
Although the ability of G protein-coupled receptors to stim-
ulate normal and aberrant cell growth has been intensely in-
vestigated (for review, see Refs. 9 and 10), the precise nature of
the molecular mechanisms underlying the transforming poten-
tial of GPCRs are still poorly understood. In this study, we have
taken advantage of the potent growth-promoting activity of
thrombin and the focus-forming potential of one of its recep-
tors, PAR-1, in NIH 3T3 cells to begin dissecting how thrombin
receptors transduce signals from the membrane to the nucleus,
thereby initiating transcriptional events participating in cell
transformation. We show here that, although Gi-coupled re-
ceptors stimulate ERK potently, only Gq and/or G13 and
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their coupled receptors, including PAR-1, can induce c-jun ex-
pression through the activation of multiple MAPK cascades
that converge in the nucleus to stimulate the transcriptional
activity of the c-jun promoter. Furthermore, we provide evi-
dence that these molecular events represent key components of
the transforming pathway utilized by PAR-1 (Fig. 10).
FIG. 6. Similar regulatory elements mediate the stimulation of the c-jun promoter by activated Gq and G13. A, shown is a schematic
representation of the c-jun promoter depicting the relative positions of the response elements. B, NIH 3T3 cells were cotransfected with the reporter
plasmid pcDNAIII--gal (0.5 g) along with pJC6, pJTX, pJSX, or pJSTX (0.1 g/plate), as indicated. X indicates the sites of point mutations in
the jAP1-binding (pJTX) and MEF2-binding (pJSX) sites. Activated forms of Gq and G13 (GqQL and G13QL, respectively) or an empty vector
(control) was included in each transfection (1 g each). 24 h later, cells were collected, and lysates were assayed for CAT and -galactosidase
activities. The data represent CAT activity normalized to -galactosidase activity present in each sample, expressed as the percentage of the pJC6
induction elicited by the activating molecules. C, cells were transfected with the reporter plasmid pjAP1-MEF2, pMEF2, or pjAP1 (0.05 g) and
pRL-null (0.01 g/plate). pcDNAIII--gal (control) or activated forms of Gq and G13 (1 g each) were added to the transfection mixture for each
reporter. Dual luciferase activities were assayed as described in the legend to Fig. 4. The data represent firefly luciferase activity normalized to
Renilla luciferase activity present in each sample, expressed as -fold induction relative to controls for each reporter, the values of which were taken
as 1. All values are the means S.E. of triplicate samples from a typical experiment. In each case, similar results were obtained in three additional
experiments.
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Once thrombin cleaves the N terminus of PAR-1, it exposes a
tethered ligand, resulting in receptor activation and the conse-
quent stimulation of G proteins of the Gi, Gq, and G13
families (12). Of interest, treatment with pertussis toxin, which
ADP-ribosylates a C-terminal threonine conserved in Go,
Gi1, Gi2, and Gi3 and uncouples them from receptor activa-
tion, has been recently shown to inhibit the transforming ac-
tivity of PAR-1 (34), suggesting a necessary role for G proteins
of the Gi family in transformation by this thrombin receptor.
Treatment with pertussis toxin has also been shown to prevent
DNA synthesis in response to thrombin, primarily by blocking
its ability to stimulate the activation of ERK (14, 48). These
observations suggest that thrombin receptors may utilize Gi
primarily to stimulate ERK. However, activation of Gi alone is
not sufficient to cause malignant conversion of NIH 3T3 cells,
as activated forms of Gi2 induce a hyperproliferative state
without causing cell transformation (49). Moreover, Gi-cou-
pled receptors such as m2 receptors do not induce cell growth or
exhibit focus-forming potential (8), although they stimulate
ERK effectively in a pertussis toxin-sensitive fashion (45).
Thus, it is likely that signaling to ERK through Gi may
represent a necessary and yet not sufficient event to stimulate
cell proliferation by certain GPCRs, including PAR-1.
In contrast to ERK stimulation, activation of c-jun expres-
sion requires the functional activity of Gq and/or G13 family
members, as reflected by the reduced c-jun expression in re-
sponse to thrombin in cells defective in Gq/G11 and by the
even more dramatically diminished c-jun expression in cells
defective in G12/13 compared with both wild-type mouse em-
bryonic fibroblasts and NIH 3T3 cells, in agreement with the
more selective coupling to G12/13 by thrombin receptors (50).
Although it is possible that these G protein double knockout
cells express fewer thrombin receptors, hence exhibiting a lim-
ited response to thrombin, these findings were further sup-
ported by the fact that m2 receptors can effectively stimulate
c-jun expression only when coexpressed with chimeric forms of
Gq and G13 that can be activated by Gi-coupled receptors. In
addition, the activated forms of Gq and G13 were alone suf-
ficient to stimulate the transcriptional activity of the c-jun
promoter, in contrast to Gi, Gs, or  subunit overexpression,
which did not elicit any demonstrable response. Together,
these data suggest that, in NIH 3T3 cells, only Gq and G13
and their coupled receptors can promote the activation of sig-
naling events leading to stimulation of the c-jun promoter and
the consequent expression of c-jun.
In the search for the mechanism by which Gq and G13
FIG. 7. Gq and G13 stimulate the activity of the c-jun promoter through the JNK, p38, and ERK5 pathways. A, NIH 3T3 cells were
transfected with pJLuc, pcDNAIII--gal, and the activated form of Gq or G13 along with MKK3AA (1 g), MEK5AA (1 g), or JIP-1 (0.1 g), as
indicated. 24 h later, cells were collected, and lysates were assayed for dual luciferase activities. The data represent firefly luciferase activity
normalized to Renilla luciferase activity present in each sample, expressed as -fold induction relative to the corresponding controls, the values of
which were taken as 1. Results are the means  S.E. of triplicate samples from a typical experiment. Similar results were obtained in three
additional experiments. B, NIH 3T3 cells were transfected with expression vectors containing HA-tagged JNK, ERK5, p38, or p38 along with
GqQL and G13QL and vector () or the corresponding positive controls () (MEKK for JNK, MEK5DD for ERK5, and MKK3 for p38 and p38).
After serum starvation, lysates were immunoprecipitated with anti-HA antibody and used for kinase reactions. 32P-Labeled substrates are
indicated. Data represent results from a typical experiment. Similar results were obtained in three additional experiments. The lower panels of
each pair of panels show expression of the HA-tagged kinases in lysates from each indicated transfectant upon analysis by Western blotting using
a specific anti-HA antibody.
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stimulate c-jun expression, we first examined which responsive
elements within the c-jun promoter respond to signals originat-
ing from the activated forms of these heterotrimeric  subunits.
Using c-jun promoter mutants and reporter plasmids contain-
ing each critical site individually or in combination, we ob-
tained information supporting that the jAP1 and MEF2 sites
are necessary and sufficient to stimulate transcription from the
c-jun promoter. Furthermore, the use of chimeric molecules,
including the DNA-binding domain of the yeast transcription
factor Gal4 fused to the transactivating domain of c-Jun and
ATF2, which bind jAP1, and MEF2A, the major MEF2 form
present in NIH 3T3 cells (25), revealed that Gq and G13 can
effectively stimulate the transcriptional activity of these fac-
tors binding the jAP1 and MEF2 response elements. This ex-
tends prior observations indicating the requirement of these
two elements for the stimulation of the c-jun promoter by
Gq-coupled receptors (25) and suggests that G13 and its cou-
pled receptors may utilize a mechanism either similar or func-
tionally related to that used by Gq to induce c-jun expression.
As each of these two sites is known to respond to the activation
of MAPK cascades, we next focused our attention on the con-
tribution of distinct MAPK pathways that are known to act on
transcription factors regulating the c-jun promoter. Indeed, we
observed that activated forms of both Gq and G13 can stim-
ulate the activity of JNK, p38, p38, and ERK5. Thus, each of
these GTPase-deficient G proteins can initiate the activity of
multiple MAPK cascades. Consistent with these observations,
we found that the use of molecules interfering with each of
these pathways can alone diminish, albeit partially, the ability
to stimulate the c-jun promoter by Gq and G13. Together,
these data support the emerging notion that Gq and G13 and
their coupled receptors can initiate the coordinated activation
of multiple MAPK pathways that converge in the nucleus to
control the activity of transcription factors regulating c-jun
expression.
In turn, how Gq and G13 stimulate JNK, p38 isoforms, and
ERK5 is not fully understood at present. Recent data indicate
that PAR-1- and m1 receptor-induced cell transformation re-
quires the activity of the small GTPase RhoA (34, 51) and that
both Gq and G13 can potently stimulate Rho activation (52–
54). In line with these findings, Rho can enhance the enzymatic
activity of JNK and p38 in certain cells (55, 56). However,
many GPCRs are also able to activate Rac1 and Cdc42, both of
which can stimulate JNK and c-jun expression (24, 56, 57) and
even transformation in NIH 3T3 (58, 59). Thus, further work
will be required to elucidate whether any of these small GT-
FIG. 8. Activated mutants of Gq and G13 stimulate the transcriptional activity of MEF2A, ATF2, and c-Jun. NIH 3T3 cells were
cotransfected with pcDNAIII-Gal4-MEF2A, pcDNAIII-Gal4-ATF2, or pcDNAIII-Gal4-c-Jun (0.05 g) along with pGal4-Luc and pRL-Null (0.1 and
0.01 g/plate, respectively). Expression vectors for GqQL and G13QL (1 g), MEKK (0.5 g), and MEK5DD  ERK5 (0.5 g each) were included
in the transfection mixtures, as indicated. 24 h after transfections, cells were collected, and lysates were assayed for dual luciferase activities. The
total amount of plasmid DNAs was adjusted with empty vector. The data represent firefly luciferase activity normalized to Renilla luciferase
activity present in each sample, expressed as -fold induction relative to the respective controls (pcDNAIII-Gal4-MEF2A, pcDNAIII-Gal4-ATF2, or
pcDNAIII-Gal4-c-Jun alone), the values of which were taken as 1. Values are the means  S.E. of triplicate samples from a typical experiment.
Nearly identical results were obtained in three additional experiments.
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Pases participate in the activation of each MAPK by Gq and
G13 in NIH 3T3 cells and, if so, to elucidate fully the nature of
the intervening mechanisms. In this regard, our present study
may provide a molecular framework in which these or other
related GTPases or signaling molecules might act, which is by
controlling the activity of specific MAPKs regulating c-jun ex-
pression in response to the stimulation of PAR-1 and other
receptors coupled to Gq and G13.
On the other hand, the role of Rho GTPases in transforma-
tion by PAR-1 may not be solely dependent on their effect on
c-jun regulation, as Rho proteins are also able to induce the
expression of another member of the AP1 family of transcrip-
tion factors, the c-fos proto-oncogene (60). Rather than through
MAPKs, this particular effect is exerted through the serum
FIG. 9. The transforming activity of
PAR-1 is decreased by molecules in-
terfering with the JNK, ERK5, and
p38 pathways. NIH 3T3 cells were
transfected by the calcium phosphate
technique with pcDNAIII--gal, pCEFL-
PAR-1, or pcDNAIII-MEKEE (1 g) alone
or in combination with JIP-1, MEK5AA,
or MKK3AA (1 g). Plates were cultured
for 3 weeks in 5% calf serum and then
fixed and stained. The data represent the
means  S.E. of triplicate samples from a
typical experiment. Similar results were
obtained in three additional experiments.
FIG. 10. Proposed model for PAR-1 signaling to the c-jun promoter and transformation. PAR-1 can initiate a signaling pathway that
induces the Gq and G13 subunits of heterotrimeric G proteins. In turn, they activate, through several members of the MAPK family, the
transcription factors bound to the jAP1 and MEF2 sites on the c-jun promoter (MEF2A, ATF2, and c-Jun), thereby enhancing its activity. Available
data suggest that c-Jun is a critical component in the transforming phenotype induced by these GPCRs in NIH 3T3 cells. Parallel pathways are
depicted and described under “Results.”
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response element within the sequence of the c-fos promoter by
a mechanism that is sensitive to changes in the actin cytoskel-
eton (60, 61). Thus, as dominant-negative c-Jun may prevent
focus formation induced by PAR-1 by blocking the activity of
both Jun-Jun homodimers and Jun-Fos heterodimers (37), it is
still possible that Rho GTPases may act downstream from
PAR-1 by enhancing c-Fos expression, thus cooperating with
those pathways promoting c-Jun expression through MAPKs to
stimulate AP1-dependent genes that are required for cell
transformation.
In summary, our results suggest that the ability to stimulate
c-jun expression can distinguish transforming from non-trans-
forming GPCRs and that this transcriptional response is de-
pendent on the stimulation of Gq and/or G13 and the subse-
quent stimulation of MAPK cascades regulating transcription
factors that control the c-jun promoter. Together, these results
define a signaling route by which thrombin receptors can signal
to the nucleus to promote the expression of growth-regulating
genes. Rather than being restricted to NIH 3T3 cells, these
findings may have broad implication in cancer biology, as
thrombin can stimulate c-jun expression in a variety of cell
types such as lung fibroblasts, astrocytoma cells, and vascular
smooth muscle cells, leading to cell growth or hypertrophy (17,
48, 62, 63). In addition, overexpression of GPCRs linked to Gq
and/or G12/13 has been reported in numerous cancers, many of
which also express their ligands, resulting in the activation of
these GPCRs in an autocrine or paracrine fashion (10). Thus, it
is likely that the biochemical route by which PAR-1 promotes
c-jun expression may represent a common mechanism partici-
pating in the promotion of cell proliferation in numerous cell
types, the contribution of which to normal and aberrant cell
growth can now begin to be explored.
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